Anand Rathi keeps Buy on Jubilant Ingrevia with Rs 900 target price
Anand Rathi kept its Buy rating on Jubilant Ingrevia after Q2 results, with EBITDA up 57% year on year and 12% above estimates.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, citing Anand Rathi's research report, Jubilant Ingrevia's EBITDA in Q2FY27 came to about Rs 2.1 billion. That is up 57% from a year earlier, up 7% from the previous quarter, and 12% above estimates.
The EBITDA margin rose 314 basis points year on year to 15.2%. The biggest contributions came from Chemical Intermediates (+697 bps) and Nutrition and Health Solutions (+280 bps). Management kept its FY27 EBITDA guidance at the upper end of the Rs 7.5-8 billion range.
The analysts raised their FY27 EBITDA estimate by 1.5% but cut FY28 EBITDA and profit forecasts by roughly 4% and 7%. In their view, the main risk is uncertainty around a large agro contract amid a commercial reset by the innovator. Their SOTP-based target price was lowered to Rs 900 per share from Rs 980.
why it matters
For the market, the takeaway is that specialty chemicals remain the main profit driver, while commodity-linked Chemical Intermediates make up a smaller share. Clarity on the agro contract will be the key point for investors to watch in the company's upcoming reports.
tags
instruments
sources
- Buy Jubilant Ingrevia; target of Rs 900: Anand Rathi — TradingView, 28 October 2026 at 05:51 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗